Tirzepatide
STRIDES
Eli Lilly · Phase 2 · Terminated · Enrollment 204
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| A: Tirzepatide Monotherapy | Obesity or overweight | n/r | 48 | n/r | n/r |
| B: Azelaprag once daily plus Tirzepatide | Obesity or overweight | n/r | 48 | n/r | n/r |
| C: Azelaprag twice daily plus Tirzepatide | Obesity or overweight | n/r | 48 | n/r | n/r |
| D: Azelaprag Monotherapy | Obesity or overweight | n/r | 48 | n/r | n/r |